Taking the BinJ/ZIKV prME virus as an example, the vaccine candidate was proven to protect male and female IFNAR−/− mice from viraemia without an adjuvant; protect male IFNAR−/− mice from testicular damage; protect maternal and fetal IFNAR−/− mice from ZIKV infection without inducing high-level neutralizing antibodies; and provide immunological protection for over 15 months [66]. This evidence concerns the gene IFNAR1 and Zika virus infectious disease.